Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company's strong presence at the 10th annual ACTRIMS Forum, where it presented two key posters on multiple sclerosis (MS). He highlighted that Immunic’s investigational drug, vidofludimus calcium, has potential neuroprotective properties that may benefit both relapsing and progressive MS patients.
One of the posters examined baseline characteristics of past progressive MS trials and contrasted them with Immunic’s CALLIPER trial, designed for non-relapsing patients with minimal inflammatory activity. The second poster explored preclinical data on the drug’s mechanism of action, emphasizing its potential to target activated microglia and support neuron survival.
Muehler noted significant engagement from the MS community at ACTRIMS, with many keenly anticipating the CALLIPER trial’s readout in April. “It’s really one of the very few late-stage drugs with a potential neuroprotective effect,” he said, adding that the data could provide new hope for progressive MS patients who currently have limited treatment options.
Stay tuned for more updates on Immunic’s progress. For more interviews, subscribe to Proactive’s YouTube channel, like this video, and turn on notifications!
#ImmunicTherapeutics #MSResearch #Neuroprotection #CALLIPERTrial #MultipleSclerosis #Biotech #DrugDevelopment #ClinicalTrials #MedicalBreakthrough #ACTRIMS